Sorafenib Induced Eruptive Melanocytic Lesions

Elizabeth E. Uhlenhake, Alice C. Watson, Peter Aronson
2013 Dermatology Online Journal  
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a patient receiving sorafenib.
doi:10.5070/d3195018184 fatcat:bthp23hwnbfzbkkvnjpj7doyjm